Assessing Flu-specific Humoral Immunity in Human Lung after Ex Vivo Lung Perfusion

评估离体肺灌注后人肺的流感特异性体液免疫

基本信息

  • 批准号:
    10088408
  • 负责人:
  • 金额:
    $ 22.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-02-01 至 2023-01-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY. Broadly reactive humoral immune responses to flu protect against viral variants. Murine data shows that the flu-specific memory B cells (Bmem) in the lung are cross-protective across a number of influenza strains and are functionally distinct from circulating and lymphoid counterparts. As yet we do not know if flu-specific Bmem in the human lung are cross-protective and bridging this knowledge gap is important to design the appropriate vaccine regimens that are universally protective against flu. Flu-specific Bmem in ex vivo lung tissues are rare and this represents a significant technical hurdle in assaying the flu-specific Bmem response in human lung tissues. In order to address this technical hurdle, this application seeks to establish a model system wherein human lung tissue is challenged with influenza virus and maintained viable after this challenge on an advanced cardiopulmonary modality called Ex Vivo Lung Perfusion or EVLP. We anticipate this model will allow us to enumerate and analyze the flu-specific Bmem response at scale in ex vivo human lung tissues. We also anticipate that this model system will allow us to compare binding reactivity to viral variants between flu- specific Bmem located in lung versus mediastinal lymph node tissues to define where cross-protective immunity exists in the respiratory tract.
项目摘要。对流感病毒的广泛反应性体液免疫反应可以保护人体免受病毒变异的侵害。鼠 数据显示,肺中的流感特异性记忆B细胞(BCLs)在许多疾病中具有交叉保护作用。 流感病毒株,并且在功能上不同于循环和淋巴对应物。我们还不知道 如果人肺中的流感特异性β-内酰胺酶具有交叉保护作用, 设计适当的疫苗方案,普遍预防流感。离体流感特异性生物素 肺组织是罕见的,这代表了在测定流感特异性的贝氏反应中的一个重要技术障碍 在人类肺组织中。为了解决这一技术障碍,本申请寻求建立一种模型, 其中人肺组织用流感病毒攻击并在该攻击后保持存活的系统 一种先进的心肺模式,称为体外肺灌注或EVLP。我们预计这一模式将 使我们能够在离体人肺组织中大规模地计数和分析流感特异性的BELF应答。我们 我还预计,这个模型系统将使我们能够比较流感病毒之间的病毒变体的结合反应性, 位于肺与纵隔淋巴结组织中的特异性抗体,以确定交叉保护性免疫的位置 存在于呼吸道中。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Anoma Nellore其他文献

Anoma Nellore的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
  • 批准号:
    19K09482
  • 财政年份:
    2019
  • 资助金额:
    $ 22.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
  • 批准号:
    2273599
  • 财政年份:
    2019
  • 资助金额:
    $ 22.28万
  • 项目类别:
    Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
  • 批准号:
    18K14964
  • 财政年份:
    2018
  • 资助金额:
    $ 22.28万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
  • 批准号:
    16K18873
  • 财政年份:
    2016
  • 资助金额:
    $ 22.28万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
  • 批准号:
    9193681
  • 财政年份:
    2016
  • 资助金额:
    $ 22.28万
  • 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
  • 批准号:
    15K18939
  • 财政年份:
    2015
  • 资助金额:
    $ 22.28万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
  • 批准号:
    26450450
  • 财政年份:
    2014
  • 资助金额:
    $ 22.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
  • 批准号:
    26462183
  • 财政年份:
    2014
  • 资助金额:
    $ 22.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
  • 批准号:
    26893253
  • 财政年份:
    2014
  • 资助金额:
    $ 22.28万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
  • 批准号:
    24701021
  • 财政年份:
    2012
  • 资助金额:
    $ 22.28万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了